Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Funda Meric-Bernstam

Showing results (121-130 of 685) with videos related to

Pageof 69
Sort By:
Cancer|October 14, 2006
Is intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer cost effective?Jacqueline S Jeruss, Kelly K Hunt, Yan Xing, et al.
Journal of Cancer|October 13, 2018
Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasisMiho Kono, Takeo Fujii, Naoko Matsuda, et al.
Journal of the American Medical Informatics Association : JAMIA|April 17, 2014
Attitudes regarding privacy of genomic information in personalized cancer therapyDeevakar Rogith, Rafeek A Yusuf, Shelley R Hovick, et al.
Human Pathology|July 28, 2019
HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological featuresQingqing Ding, Hui Chen, Bora Lim, et al.
Oncotarget|May 15, 2015
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Fanny Le Du, Bedrich L Eckhardt, Bora Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2024
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 PatientsFunda Meric-Bernstam, Antoine Hollebecque, Junji Furuse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
Determinants of rapamycin sensitivity in breast cancer cellsWoo-Chul Noh, Wallace H Mondesire, Junying Peng, et al.
Oncotarget|September 7, 2019
TAK228 enhances antitumor activity of eribulin in triple negative breast cancerNicci Owusu-Brackett, Kurt W Evans, Argun Akcakanat, et al.
Cancer|July 30, 2011
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancerSoley Bayraktar, Leonel F Hernadez-Aya, Xiudong Lei, et al.
JCO Clinical Cancer Informatics|September 25, 2019
Operationalization of Next-Generation Sequencing and Decision Support for Precision OncologyJia Zeng, Amber Johnson, Md Abu Shufean, et al.
Pageof 69

Showing results (121-130 of 685) with videos related to

Sort By:
Pageof 69
Cancer|October 14, 2006
Is intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer cost effective?Jacqueline S Jeruss, Kelly K Hunt, Yan Xing, et al.
Journal of Cancer|October 13, 2018
Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasisMiho Kono, Takeo Fujii, Naoko Matsuda, et al.
Journal of the American Medical Informatics Association : JAMIA|April 17, 2014
Attitudes regarding privacy of genomic information in personalized cancer therapyDeevakar Rogith, Rafeek A Yusuf, Shelley R Hovick, et al.
Human Pathology|July 28, 2019
HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological featuresQingqing Ding, Hui Chen, Bora Lim, et al.
Oncotarget|May 15, 2015
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Fanny Le Du, Bedrich L Eckhardt, Bora Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2024
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 PatientsFunda Meric-Bernstam, Antoine Hollebecque, Junji Furuse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
Determinants of rapamycin sensitivity in breast cancer cellsWoo-Chul Noh, Wallace H Mondesire, Junying Peng, et al.
Oncotarget|September 7, 2019
TAK228 enhances antitumor activity of eribulin in triple negative breast cancerNicci Owusu-Brackett, Kurt W Evans, Argun Akcakanat, et al.
Cancer|July 30, 2011
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancerSoley Bayraktar, Leonel F Hernadez-Aya, Xiudong Lei, et al.
JCO Clinical Cancer Informatics|September 25, 2019
Operationalization of Next-Generation Sequencing and Decision Support for Precision OncologyJia Zeng, Amber Johnson, Md Abu Shufean, et al.
Pageof 69